| 211 | Humans |
| 175 | Antibodies, Monoclonal, Humanized |
| 133 | Female |
| 105 | Male |
| 103 | Arthritis, Rheumatoid |
| 101 | Antirheumatic Agents |
| 97 | Middle Aged |
| 75 | Treatment Outcome |
| 74 | Adult |
| 62 | Aged |
| 37 | Antibodies, Monoclonal |
| 34 | Drug Therapy, Combination |
| 30 | Tumor Necrosis Factor-alpha |
| 29 | Severity of Illness Index |
| 29 | Interleukin-6 |
| 29 | Glucocorticoids |
| 27 | Methotrexate |
| 27 | Biological Products |
| 25 | Retrospective Studies |
| 25 | Receptors, Interleukin-6 |
| 25 | Immunosuppressive Agents |
| 19 | Rituximab |
| 18 | Giant Cell Arteritis |
| 17 | Prospective Studies |
| 16 | Remission Induction |
| 16 | Abatacept |
| 15 | Follow-Up Studies |
| 14 | Young Adult |
| 14 | Prednisone |
| 14 | Adolescent |
| 13 | France |
| 13 | Biomarkers |
| 12 | Time Factors |
| 12 | Still's Disease, Adult-Onset |
| 12 | Biological Therapy |
| 12 | Animals |
| 11 | Double-Blind Method |
| 11 | Disease Progression |
| 11 | Cytokines |
| 11 | Child |
| 11 | Adrenal Cortex Hormones |
| 10 | Takayasu Arteritis |
| 10 | Risk Factors |
| 10 | Prognosis |
| 10 | Arthritis, Juvenile |
| 9 | Polychondritis, Relapsing |
| 9 | Inflammation |
| 9 | Immunologic Factors |
| 9 | Etanercept |
| 9 | Drug Resistance |
| 9 | C-Reactive Protein |
| 9 | Aged, 80 and over |
| 9 | Adalimumab |
| 8 | Risk Assessment |
| 8 | Polymyalgia Rheumatica |
| 8 | Infusions, Intravenous |
| 8 | Anti-Inflammatory Agents |
| 7 | Uveitis |
| 7 | Recurrence |
| 7 | Injections, Subcutaneous |
| 7 | Drug Administration Schedule |
| 7 | Cohort Studies |
| 7 | Child, Preschool |
| 6 | Randomized Controlled Trials as Topic |
| 6 | Mice |
| 6 | Infliximab |
| 6 | Drug Eruptions |
| 6 | Castleman Disease |
| 6 | Behcet Syndrome |
| 5 | Registries |
| 5 | Outcome Assessment, Health Care |
| 5 | Joints |
| 5 | Incidence |
| 5 | Immunocompromised Host |
| 5 | Drug Substitution |
| 5 | Diagnosis, Differential |
| 5 | Clinical Trials as Topic |
| 5 | Chronic Disease |
| 5 | Biological Factors |
| 5 | Antibodies, Monoclonal, Murine-Derived |
| 4 | Tomography, X-Ray Computed |
| 4 | T-Lymphocytes, Regulatory |
| 4 | Surveys and Questionnaires |
| 4 | Spondylitis, Ankylosing |
| 4 | Scleroderma, Systemic |
| 4 | Rheumatic Diseases |
| 4 | Radiography |
| 4 | Psoriasis |
| 4 | Positron-Emission Tomography |
| 4 | Phenotype |
| 4 | Multivariate Analysis |
| 4 | Molecular Targeted Therapy |
| 4 | Macrophage Activation Syndrome |
| 4 | Lymphohistiocytosis, Hemophagocytic |
| 4 | Interleukins |
| 4 | Immunoconjugates |
| 4 | Herpesvirus 4, Human |
| 4 | Fever |
| 4 | Europe |
| 4 | Drug-Related Side Effects and Adverse Reactions |
| 4 | Drug Monitoring |
| 4 | Dose-Response Relationship, Drug |
| 4 | Disease Models, Animal |
| 4 | Disease Management |
| 4 | Cardiovascular Diseases |
| 4 | Body Mass Index |
| 4 | Arthritis |
| 4 | Anti-Inflammatory Agents, Non-Steroidal |
| 3 | Tumor Necrosis Factor Inhibitors |
| 3 | Treatment Failure |
| 3 | Th17 Cells |
| 3 | Spondylarthritis |
| 3 | Skin |
| 3 | Skin Neoplasms |
| 3 | Signal Transduction |
| 3 | Polymorphism, Single Nucleotide |
| 3 | Pain Measurement |
| 3 | Opportunistic Infections |
| 3 | Network Meta-Analysis |
| 3 | Neoplasms |
| 3 | Maintenance Chemotherapy |
| 3 | Lung |
| 3 | Longitudinal Studies |
| 3 | Leukocytes, Mononuclear |
| 3 | Interleukin 1 Receptor Antagonist Protein |
| 3 | Injections, Intravenous |
| 3 | Inflammatory Bowel Diseases |
| 3 | Immunoglobulins, Intravenous |
| 3 | Evidence-Based Medicine |
| 3 | Enzyme-Linked Immunosorbent Assay |
| 3 | Drug Hypersensitivity |
| 3 | Cytomegalovirus |
| 3 | Cross-Sectional Studies |
| 3 | Comorbidity |
| 3 | Collagen Type I |
| 3 | Certolizumab Pegol |
| 3 | Cell Proliferation |
| 3 | Bone and Bones |
| 3 | Blood Sedimentation |
| 3 | Autoimmune Diseases |
| 3 | Autoantibodies |
| 3 | Arthritis, Infectious |
| 3 | Aortitis |
| 3 | Antineoplastic Agents |
| 3 | Antigens, CD |
| 2 | Withholding Treatment |
| 2 | Vital Capacity |
| 2 | Virus Activation |
| 2 | Viral Load |
| 2 | Vasculitis |
| 2 | Ustekinumab |
| 2 | T-Lymphocyte Subsets |
| 2 | Systemic Vasculitis |
| 2 | Synovitis |
| 2 | Syndrome |
| 2 | Survival Analysis |
| 2 | Statistics, Nonparametric |
| 2 | Skin Diseases |
| 2 | Sjogren's Syndrome |
| 2 | Sirolimus |
| 2 | Sarcoidosis |
| 2 | Sampling Studies |
| 2 | Salvage Therapy |
| 2 | Quality of Life |
| 2 | Pyrroles |
| 2 | Pyrimidines |
| 2 | PubMed |
| 2 | Proportional Hazards Models |
| 2 | Practice Guidelines as Topic |
| 2 | Positron Emission Tomography Computed Tomography |
| 2 | Polyethylene Glycols |
| 2 | Pneumonia |
| 2 | Peptides |
| 2 | Peptides, Cyclic |
| 2 | Patient Safety |
| 2 | Osteocalcin |
| 2 | Neutrophils |
| 2 | Neuromyelitis Optica |
| 2 | Mutation |
| 2 | Mice, Inbred C57BL |
| 2 | Melanoma |
| 2 | Medication Therapy Management |
| 2 | Magnetic Resonance Imaging |
| 2 | Lymphoma |
| 2 | Logistic Models |
| 2 | Lipoproteins |
| 2 | Lipid Metabolism |
| 2 | Leflunomide |
| 2 | Knee Joint |
| 2 | Killer Cells, Natural |
| 2 | Kaplan-Meier Estimate |
| 2 | Interleukin-6 Receptor alpha Subunit |
| 2 | Interleukin-1beta |
| 2 | Interleukin-17 |
| 2 | Interleukin-10 |
| 2 | Induction Chemotherapy |
| 2 | Immunotherapy |
| 2 | Immunomodulation |
| 2 | Immunoglobulins |
| 2 | Immunoglobulin Fab Fragments |
| 2 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 2 | Hospitals, University |
| 2 | Herpesvirus 3, Human |
| 2 | Health Status |
| 2 | Hand Joints |
| 2 | Genetic Predisposition to Disease |
| 2 | Fluorodeoxyglucose F18 |
| 2 | Flow Cytometry |
| 2 | Fatigue |
| 2 | Edema |
| 2 | Drugs, Investigational |
| 2 | Drug Interactions |
| 2 | Drug Hypersensitivity Syndrome |
| 2 | Desensitization, Immunologic |
| 2 | Cytomegalovirus Infections |
| 2 | Crohn Disease |
| 2 | Critical Illness |
| 2 | Collagen Type II |
| 2 | Cell Line, Tumor |
| 2 | Case-Control Studies |
| 2 | Cartilage, Articular |
| 2 | CD4-Positive T-Lymphocytes |
| 2 | Body Weight |
| 2 | Biomarkers, Tumor |
| 2 | Bayes Theorem |
| 2 | Azathioprine |
| 2 | Arthritis, Psoriatic |
| 2 | Arthritis, Experimental |
| 2 | Arthralgia |
| 2 | Apyrase |
| 2 | Antineoplastic Agents, Immunological |
| 2 | Antifungal Agents |
| 2 | Anti-Bacterial Agents |
| 2 | Amyloidosis |
| 1 | Voriconazole |
| 1 | Vitrectomy |
| 1 | Vitiligo |
| 1 | Vitamins |
| 1 | Vitamin D |
| 1 | Visual Acuity |
| 1 | Vaccination |
| 1 | Uveal Neoplasms |
| 1 | United States |
| 1 | United Kingdom |
| 1 | Ultrasonography, Doppler |
| 1 | Tumor Necrosis Factors |
| 1 | Tumor Microenvironment |
| 1 | Tubulin Modulators |
| 1 | Tryptophan |
| 1 | Tretinoin |
| 1 | Trastuzumab |
| 1 | Transplantation, Homologous |
| 1 | Tomography, Optical Coherence |
| 1 | Toll-Like Receptors |
| 1 | Thrombin |
| 1 | Temporal Arteries |
| 1 | Tandem Mass Spectrometry |
| 1 | TNF-Related Apoptosis-Inducing Ligand |
| 1 | T-Lymphocytes |
| 1 | T-Lymphocytes, Cytotoxic |
| 1 | Symptom Assessment |
| 1 | Survival Rate |
| 1 | Superoxide Dismutase |
| 1 | Stomatitis, Aphthous |
| 1 | Steroids |
| 1 | Spinal Cord Compression |
| 1 | Societies, Medical |
| 1 | Smoking |
| 1 | Skin Tests |
| 1 | Sex Factors |
| 1 | Serum Amyloid A Protein |
| 1 | Sensory Receptor Cells |
| 1 | Sensitivity and Specificity |
| 1 | Semaphorins |
| 1 | Self Report |
| 1 | Secondary Prevention |
| 1 | Scleroderma, Diffuse |
| 1 | Scabies |
| 1 | Sarcoidosis, Pulmonary |
| 1 | Safety Management |
| 1 | STAT3 Transcription Factor |
| 1 | Risk |
| 1 | Risk Management |
| 1 | Rifampin |
| 1 | Rheumatology |
| 1 | Rheumatic Fever |
| 1 | Retreatment |
| 1 | Retina |
| 1 | Respiratory Insufficiency |
| 1 | Respiration, Artificial |
| 1 | Renal Replacement Therapy |
| 1 | Referral and Consultation |
| 1 | Reference Values |
| 1 | Receptors, Tumor Necrosis Factor |
| 1 | Receptors, Tumor Necrosis Factor, Type I |
| 1 | Receptors, Interleukin-1 Type I |
| 1 | Receptors, Chimeric Antigen |
| 1 | Receptors, Antigen, B-Cell |
| 1 | Real-Time Polymerase Chain Reaction |
| 1 | Rare Diseases |
| 1 | Range of Motion, Articular |
| 1 | Radiopharmaceuticals |
| 1 | Radionuclide Imaging |
| 1 | ROC Curve |
| 1 | RNA, Ribosomal, 16S |
| 1 | RNA, Neoplasm |
| 1 | Quinazolines |
| 1 | Quality Control |
| 1 | Pyrin |
| 1 | Pyrazoles |
| 1 | Pyrazines |
| 1 | Purpura, Thrombotic Thrombocytopenic |
| 1 | Pulmonary Fibrosis |
| 1 | Pulmonary Emphysema |
| 1 | Pulmonary Aspergillosis |
| 1 | Psychiatric Status Rating Scales |
| 1 | Proteolysis |
| 1 | Protein Kinase Inhibitors |
| 1 | Protein Array Analysis |
| 1 | Proof of Concept Study |
| 1 | Programmed Cell Death 1 Receptor |
| 1 | Procollagen |
| 1 | Primary Dysautonomias |
| 1 | Presenteeism |
| 1 | Prenatal Exposure Delayed Effects |
| 1 | Pregnancy |
| 1 | Pregnancy Outcome |
| 1 | Pregnancy Complications |
| 1 | Prednisolone |
| 1 | Predictive Value of Tests |
| 1 | Preconception Care |
| 1 | Precision Medicine |
| 1 | Polymerase Chain Reaction |
| 1 | Platelet-Rich Plasma |
| 1 | Platelet Aggregation |
| 1 | Plasmapheresis |
| 1 | Placebos |
| 1 | Piperidines |
| 1 | Pilot Projects |
| 1 | Pharyngitis |
| 1 | Peptide Fragments |
| 1 | Pedigree |
| 1 | Pediatrics |
| 1 | Patient-Centered Care |
| 1 | Patient Satisfaction |
| 1 | Patient Reported Outcome Measures |
| 1 | Patient Preference |
| 1 | Patient Participation |
| 1 | Patient Education as Topic |
| 1 | Pasteurella multocida |
| 1 | Pasteurella Infections |
| 1 | Parvovirus B19, Human |
| 1 | Pain |
| 1 | Pain Management |
| 1 | Overweight |
| 1 | Ovarian Neoplasms |
| 1 | Osteoporosis |
| 1 | Osteogenesis |
| 1 | Osteitis |
| 1 | Osmolar Concentration |
| 1 | Organic Anion Transporters |
| 1 | Oral Ulcer |
| 1 | Observational Studies as Topic |
| 1 | Nivolumab |
| 1 | Nevus |
| 1 | Neutropenia |
| 1 | Nervous System Diseases |
| 1 | Nerve Growth Factor |
| 1 | Nerve Fibers |
| 1 | Neoplasm Metastasis |
| 1 | Myositis |
| 1 | Myelodysplastic Syndromes |
| 1 | Myelitis |
| 1 | Myelin-Oligodendrocyte Glycoprotein |
| 1 | Mycophenolic Acid |
| 1 | Muscular Diseases |
| 1 | Multimodal Imaging |
| 1 | Monte Carlo Method |
| 1 | Monocytes |
| 1 | Mice, Transgenic |
| 1 | Mice, Knockout |
| 1 | Mice, Inbred NOD |
| 1 | Mice, Inbred DBA |
| 1 | Methylprednisolone |
| 1 | Mesenteric Ischemia |
| 1 | Meningoencephalitis |
| 1 | Meningococcal Vaccines |
| 1 | Meningitis |
| 1 | Meningitis, Aseptic |
| 1 | Matrix Metalloproteinase 3 |
| 1 | Maternal-Fetal Exchange |
| 1 | Magnetic Resonance Angiography |
| 1 | Macular Edema |
| 1 | Macrophages |
| 1 | Macrophage Activation |
| 1 | Lymphocytes, Tumor-Infiltrating |
| 1 | Lymphocyte Count |
| 1 | Lymphocyte Activation |
| 1 | Lymphadenopathy |
| 1 | Lupus Erythematosus, Systemic |
| 1 | Lung Neoplasms |
| 1 | Locomotion |
| 1 | Liver Neoplasms |
| 1 | Liver Failure |
| 1 | Liver Diseases |
| 1 | Lisuride |
| 1 | Lipoprotein(a) |
| 1 | Lipopolysaccharides |
| 1 | Lipids |
| 1 | Linear Models |
| 1 | Levofloxacin |
| 1 | Leukocyte Count |
| 1 | Leptin |
| 1 | Legionellosis |
| 1 | Legionellaceae |
| 1 | Leg |
| 1 | Lactation |
| 1 | Kidney Transplantation |
| 1 | Kidney Function Tests |
| 1 | Kidney Failure, Chronic |
| 1 | Janus Kinases |
| 1 | Ivermectin |
| 1 | Itraconazole |
| 1 | Isoxazoles |
| 1 | Isoantibodies |
| 1 | Ipilimumab |
| 1 | Internationality |
| 1 | International Cooperation |
| 1 | Internal Medicine |
| 1 | Interleukin-8 |
| 1 | Interleukin-33 |
| 1 | Interferons |
| 1 | Interferon-alpha |
| 1 | Intercellular Signaling Peptides and Proteins |
| 1 | Insulin Resistance |
| 1 | Injections, Intra-Articular |
| 1 | Infusion Pumps |
| 1 | Inflammation Mediators |
| 1 | Infections |
| 1 | Infant, Newborn |
| 1 | Indoles |
| 1 | Indoleamine-Pyrrole 2,3,-Dioxygenase |
| 1 | In Vitro Techniques |
| 1 | Immunotherapy, Adoptive |
| 1 | Immunophenotyping |
| 1 | Immunohistochemistry |
| 1 | Immunoglobulin G |
| 1 | Immunoglobulin E |
| 1 | Immunogenetics |
| 1 | Immunization |
| 1 | Immunity, Innate |
| 1 | Immune Tolerance |
| 1 | Illness Behavior |
| 1 | Ileitis |
| 1 | Hypothalamus |
| 1 | Hypertension |
| 1 | Hypertension, Pulmonary |
| 1 | Hypertension, Portal |
| 1 | Hydrogen-Ion Concentration |
| 1 | Hydrocortisone |
| 1 | Hydrocarbons |
| 1 | Hutchinson's Melanotic Freckle |
| 1 | Hospitals, Special |
| 1 | Hospitals, Pediatric |
| 1 | Hospitals, Community |
| 1 | Histoplasmosis |
| 1 | Histoplasma |
| 1 | Hidradenitis Suppurativa |
| 1 | Herpes Zoster |
| 1 | Herpes Zoster Vaccine |
| 1 | Herpes Zoster Ophthalmicus |
| 1 | Heredity |
| 1 | Hepatocytes |
| 1 | Hepatitis E |
| 1 | Hepatitis C, Chronic |
| 1 | Hepatitis B, Chronic |
| 1 | Hepatitis B Vaccines |
| 1 | Hepatic Stellate Cells |
| 1 | Hematopoietic Stem Cell Transplantation |
| 1 | Healthy Volunteers |
| 1 | Health Surveys |
| 1 | Health Expenditures |
| 1 | Haplotypes |
| 1 | Half-Life |
| 1 | Hair |
| 1 | HLA Antigens |
| 1 | Granzymes |
| 1 | Granuloma |
| 1 | Granulocyte-Macrophage Colony-Stimulating Factor |
| 1 | Graft Survival |
| 1 | Graft Rejection |
| 1 | Glomerulonephritis, IGA |
| 1 | Glomerular Filtration Rate |
| 1 | Genotype |
| 1 | Genetic Association Studies |
| 1 | Gene Regulatory Networks |
| 1 | Gene Expression Regulation, Enzymologic |
| 1 | Gene Expression Profiling |
| 1 | GTP-Binding Protein alpha Subunits, Gs |
| 1 | Foot Joints |
